Physician profile
Roy E Abendroth
NPI 1811988421
$1,138.74
in general payments reported to CMS, 2019-2025
14 companies · $32.59 in 2025
The $32.59 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.91 · 2020: $18.52 · 2021: $426 · 2022: $92.82 · 2023: $219 · 2024: $266 · 2025: $32.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $196.17 | 2021 | |
| Novocure INC. | $187.43 | 2023-2024 | Optune |
| Zap Surgical Systems, INC. | $154.05 | 2023 | Zap-X Treatment Planning Software, Zap-X Mv Imager, Zap-X Treatment Delivery Software |
| Puma Biotechnology, INC. | $123.00 | 2021 | |
| Seagen INC. | $107.08 | 2021 | |
| Reflexion Medical, INC. | $88.73 | 2022-2023 | Reflexion Medical Radiotherapy System |
| Regeneron Healthcare Solutions, INC. | $72.88 | 2022-2024 | Libtayo |
| Merck Sharp & Dohme LLC | $56.30 | 2019-2020 | |
| Gt Medical Technologies, INC | $32.59 | 2025 | Gammatile |
| Novartis Pharmaceuticals Corporation | $30.45 | 2024 | |
| Coherus Oncology, INC. | $25.05 | 2024 | |
| Angiodynamics, INC. | $23.91 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $22.22 | 2019 | |
| Genzyme Corporation | $18.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Abendroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.